Treatment of mice with dextran sulfate sodium-induced colitis with human interleukin 10 secreted by transformed Bifidobacterium longum

Molecular Pharmaceutics

Volumn 8, Issue 2, 2011, Pages 488-497

  Yao, Jun ^a   Wang, Jian Yao ^b   Lai, Ming Guang ^a   Li, Ying Xue ^a   Zhu, Hui Ming ^a   Shi, Rui Yue ^a   Mo, Jing ^c   Xun, An Ying ^d   Jia, Chun Hong ^e   Feng, Ju Ling ^a   Wang, Li Sheng ^a   Zeng, Wei Sen ^e   Liu, Lei ^b  

^a JINAN UNIVERSITY   (China)

^b SHENZHEN CHILDREN'S HOSPITAL   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Bifidobacterium longum; BL hIL 10; interleukin 10; ulcerative colitis

Indexed keywords

CYTOKINE; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIFIDOBACTERIUM LONGUM; CD4+ CD25+ T LYMPHOCYTE; COLITIS; DRUG DELIVERY SYSTEM; DRUG EFFECT; MALE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADMINISTRATION, ORAL; ANIMALS; BIFIDOBACTERIUM; BLOTTING, WESTERN; COLITIS; CYTOKINES; DEXTRAN SULFATE; DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; MONOCYTES; NF-KAPPA B; PEROXIDASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY;

EID: 79953833268     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100331r     Document Type: Article

References (44)

1. Fiocchi, C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115, 182-205. (Pubitemid 28307304)
2. Kennedy, R. J.; Hoper, M.; Deodhar, K.; Erwin, P. J.; Kirk, S. J.; Gardiner, K. R. Interleukin 10-deficient colitis: new similarities to human inflammatory bowel disease. Br. J. Surg. 2000, 87 (10), 1346-1351.
3. Steidler, L.; Hans, W.; Schotte, L.; Neirynck, S.; Obermeier, F.; Falk, W.; Fiers, W.; Remaut, E. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289 (5483), 1352-1355. (Pubitemid 30656052)
4. Hofstetter, C.; Kleen, M.; Habler, O.; Allmeling, A. M.; Krombach, F.; Zwissler, B. Recombinant human interleukin-10 attenuates TNFalpha production by porcine monocytes. Eur. J. Med. Res. 1998, 3 (6), 299-303.
5. Powrie, F.; Leach, M. W.; Mauze, S.; Menon, S.; Caddle, L. B.; Coffman, R. L. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+T cells. Immunity 1994, 1, 553-562.
6. Tomoyose, M.; Mitsuyama, K.; Ishida, H.; et al. Role of interleukin-10 in a murine model of dextran sulfate sodium-induced colitis. Scand. J. Gastroenterol. 1998, 33, 435-440.
7. Fedorak, R. N.; Gangl, A.; Elson, C. O.; et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 2000, 119, 1473-1482.
8. Chernoff, A. E.; Granowitz, E. V.; Shapiro, L.; Vannier, E.; Lonneman, G.; Angel, J. B.; Kennedy, J. S.; Rabson, A. R.; Wolff, S. M.; Dinarello, C. A. A randomized controlled trial of rIL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J. Immunol. 1995, 154, 5492-5499.
9. Sartor, R. B. Induction of mucosal immune responses by bacteria and bacterial components. Curr. Opin. Gastroenterol. 2001, 17, 555-561.
10. van der Wiel-Korstanje, J. A.; Winkler, K. C. The faecal flora in ulcerative colitis. J. Med. Microbiol. 1975, 8, 491-501.
11. Matsuda, H.; Fujiyama, Y.; Andoh, A.; Ushijima, T.; Kijinami, T.; Bamba, T. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J. Gastroenterol. Hepatol. 2000, 15, 61-68.
12. Cummings, J.; Macfarlane, G.; Macfarlane, S. Intestinal bacteria and ulcerative colitis. Curr. Issues Intest. Microbiol. 2003, 4, 9-20.
13. De Simone, C.; Rosati, E.; Moretti, S.; Salvadori, B.; Vesely, R.; Jirillo, E. Probiotics and stimulation of the immune response. Eur. J. Clin. Nutr. 1991, 45, 32-34.
14. Elmer, G. W.; Surawicz, C. M.; McFarl, L. V. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA, J. Am. Med. Assoc. 1996, 275, 870-8766.
15. Orrhage, K.; Sillerstrom, E.; Gustafsson, J. A.; Nord, C. E.; Rafter, J. Binding of mutagenic heterocyclic amines by intestinal and lactic acid bacteria. Mutat. Res. 1994, 311, 239-248.
16. Setoyama, H.; Imaoka, A.; Ishikawa, H.; Umesaki, Y. Prevention of gut inflammation by Bifidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients. Microbes Infect. 2003, 5, 115-122. (Pubitemid 36316053)
17. He, M. Q.; Xie, H. J.; Zhu, Y. L.; Zhang, M. W.; Kang, B. A study of the microflora population in contents collected from jejunum and healthy piglets. Chin. J. Anim. Vet. Sci. 1986, 17 (4), 276-283.
18. Lindsay, J. O.; Ciesielski, C. J.; Scheinin, T.; Brennan, F. M.; Hodgson, H. J. Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut 2004, 53 (5), 774.
19. Zhu, Z. S.; Wang, L. S.; Zeng, W. S.; Zheng, Y. J.; Luo, S. Q.; Li, Y. X. Isolation and identification of a Bifidobacterium strain with a plasmid polymerase by PCR. J. Microecol. (China) 2007, 19, 321-323.
20. Long, R. T.; Zeng, W. S.; Chen, L. Y.; Guo, J.; Lin, Y. Z.; Huang, Q. S.; Luo, S. Q. Bifidobacterium as an oral delivery carrier of oxyntomodulin for obesity therapy: inhibitory effects on food intake and body weight in overweight mice. Int. J. Obes. (London) 2010, 34, 712-719.
21. Schroecksnadel, S.; Jenny, M.; Kurz, K.; Klein, A.; Ledochowski, M.; Uberall, F.; Fuchs, D. LPS-induced NF-kappaB expression in THP-1Blue cells correlates with neopterin production and activity of indoleamine 2,3-dioxygenase. Biochem. Biophys. Res. Commun. 2010, 399 (4), 642-646.
22. Cooper, H. S.; Murthy, S. N.; Shah, R. S.; Sedergran, D. J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 1993, 69, 238-249.
23. Hirata, I.; Yasumoto, S.; Toshina, K.; Inoue, T.; Nishikawa, T.; Murano, N.; Murano, M.; Wang, F. Y.; Katsu, K. Evaluation of the effect of pyrrolidine dithiocarbamate in suppressing inflammation in mice with dextran sodium sulfate-induced colitis. World J. Gastroenterol. 2007, 13, 1666-1671.
24. Renard, P.; Ernest, I.; Houbion, A. M.; Le Calvez, H.; Raes, M.; Remacle, J. Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res. 2001, 29, E21.
25. Howard, M.; O'Garra, A. Biological properties of IL-10. Immunol. Today 1992, 13, 198.
26. Moore, K. W.; O'Garra, A.; de Waal Malefyt, R.; Vieira, P.; Mosmann, T. R. Interleukin-10. Annu. Rev. Immunol. 1993, 11, 165.
27. Murthy, P. K.; Dennis, V. A.; Lasater, B. L.; Philipp, M. T. Interleukin-10 modulates proinflammatory cytokines in the human monocytic cell line THP-1 stimulated with Borrelia burgdorferi lipoproteins. Infect. Immun. 2000, 68, 6663-6669.
28. Karin, M. The beginning of the end: I.B kinase and NF-.B activation. J. Biol. Chem. 1999, 274, 27339-27342.
29. YANG, J.; Cui, S. L.; Long, Y. M. Experimental study on micromolecule polypeptide combining with NEMO-binding domain treating on rats of ulcerative colitis. J. Guangdong Pharm. Coll. 2009, 25, 180-183.
30. Ogata, H.; Hibi, T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr. Pharm. Des. 2003, 9, 1107-1113.
31. Xie, Y. N.; Wu, Z. J.; Zhao, H. L. Study on the role of curcumin for treating trinitrobenzene sulphonic acid (TNBS)-induced ulcerative colitis in mice. Pract. J. Med. Pharm. 2009, 26, 46-48.
32. Dal Sasso, M.; Culici, M.; Guffanti, E. E.; Bianchi, T.; Fonti, E.; Braga, P. C. A combination of budesonide and the SH-metabolite I of erdosteine acts synergistically in reducing chemiluminescence during human neutrophil respiratory burst. Pharmacology 2005, 74, 127-134. (Pubitemid 40981098)
33. Lindsay, J.; Van Montfrans, C.; Brennan, F.; Van Deventer, S.; Drillenburg, P.; Hodgson, H.; Te Velde, A.; SolRodriguez Pena, M. IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther. 2002, 9 (24), 1715-1721.
34. Schreiber, S.; Heinig, T.; Thiele, H.; Raedler, A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995, 108, 1434-1444.
35. Hajj Hussein, I. A.; Tohme, R.; Barada, K.; Mostafa, M. H.; Freund, J. N.; Jurjus, R. A.; Karam, W.; Jurjus, A. Inflammatory bowel disease in rats: bacterial and chemical interaction. World J. Gastroenterol. 2008, 14, 4028-4039.
36. Camuesco, D.; Gálvez, J.; Nieto, A.; Comalada, M.; Rodríguez-Cabezas, M. E.; Concha, A.; Xaus, J.; Zarzuelo, A. Dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, attenuates colonic inflammation in rats with DSS-induced colitis. J. Nutr. 2005, 135, 687-694. (Pubitemid 40464089)
37. Powrie, F.; Read, S.; Mottet, C.; et al. Control of immune pathology by regulatory T cells. Novartis Found. Symp. 2003, 252, 92-98.
38. Liu, H.; Hu, B.; Xu, D.; et al. CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4. J. Immunol. 2003, 171, 5012-5017.
39. Sitohy, B.; Hammarström, S.; Danielsson, A.; et al. Basal lymphoid aggregates in ulcerative colitis colon: a site for regulatory T cell action. Clin. Exp. Immunol. 2008, 151, 326-333.
40. Hori, S.; Nomura, T.; Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299, 1057-1061. (Pubitemid 36222930)
41. Fontenot, J. D.; Gavin, M. A.; Rudensky, A. Y. Foxp3 programs the development and function of CD4 CD25 regulatory T cells. Nat. Immunol. 2003, 4, 330-333.
42. Kamikozuru, K.; Fukunaga, K.; Hirota, S.; Hida, N.; Ohda, Y.; Yoshida, K.; Yokoyama, Y.; Tozawa, K.; Kawa, K.; Iimuro, M.; Nagase, K.; Saniabadi, A. R.; Nakamura, S.; Miwa, H.; Matsumoto, T. The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease. Clin. Exp. Immunol. 2009, 156, 320-327.
43. Moon, G.-S.; Pyun, Y.-R.; Park, M. S.; Ji, G. E.; Kim, W. J. Secretion of recombinant pediocin PA-1 by Bifidobacterium longum, using the signal sequence for bifidobacooterial α-amylase. Appl. Environ. Microbiol. 2005, 72, 5630-5632.
44. Eaden, J. A.; Abrams, K. R.; Mayberry, J. F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48, 526-535.